ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcomes of Hlai Kidney Transplants in Patients with Cpra 100% After Desensitization

A. A. Vo1, J. Tang1, S. Williamson1, C. Meyers1, E. Huang1, X. Zhang2, M. Haas3, A. Peng1, R. Najjar1, S. Supreet1, N. Ammerman1, K. Lim1, M. Gillespie1, N. Badash1, S. Jordan1

1Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, 2HLA Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA, 3Pathology, Cedars Sinai Medical Ctr, Los Angeles, CA

Meeting: 2022 American Transplant Congress

Abstract number: 1023

Keywords: Alloantibodies, Highly-sensitized, Kidney transplantation, Rejection

Topic: Clinical Science » Kidney » 36 - Kidney Immunosuppression: Desensitization

Session Information

Session Name: Kidney Immunosuppression: Desensitization

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: The KAS implementation was aimed at increasing access to kidney transplantation in highly HLA sensitized (HS) patients. However, combining desensitization (DES) + KAS could improve transplant rates and outcomes for the most HS (>99.5%) patients. Here we report outcomes for cPRA 100% sensitized patients transplanted after DES.

*Methods: HS patients underwent DES primarily w. IVIG + anti-CD20 ± PLEX. Unresponsive patients received DES w. anti-IL-6/IL-6R or Daratumumab (anti-CD38). Acceptable CMX criteria for transplantation included: Negative CDC, T&B-FCMX ≤225MCS and DSA ≤10,000MFI post DES. Unacceptable antigens were defined as MFI>15,000. Outcomes included rate of ABMR, patient & graft survival & eGFR @12M. All transplanted HS patients received induction w. alemtuzumab and maintained w. tac/mmf/pred.

*Results: From 12/2018-8/2021, 33 HS patients w. cPRA 100% {G1: cPRA<99.95 (N=29), and G2: cPRA≥99.95 (N=4)} received HLAi transplants (Tx). Briefly, mean time from dialysis to Tx was 72±43M vs. 109±71M and mean time from end of 1st DES to Tx was 11±14M vs. 23±19M, G1 vs. G2. Mean number of rounds of DES needed was 1.6±0.79 (G1) vs. 2.75±1.5 (G2). DGF was seen in 52% (G1) vs. 100% (G2). FCMX+/DSA+ or FCMX-/DSA+ at Tx were 59% (G1) vs. 100% (G2) (Table 1). Figure 1 shows rejection by FCMX/DSA and by cPRA status. Eight patients (24%) developed AMR or mixed rejection {6 (G1) vs. 2 (G2)}. Patient & graft survival were 97%/93% vs. 100%/100% and eGFR @12M was 66±30 vs. 53±14 ml/min/1.73m2, G1 vs. G2, respectively.

*Conclusions: Overall, transplantation in HS patients w. cPRA 100% was associated w. longer time to transplant after 1st round of DES, higher rate of FCMX+/DSA+ @transplant and >50% w. DGF. Despite higher immunologic risk, patient & graft survival were acceptable and eGFRs were similar to non-HLAi patients @12M. Recent data showed that graft survival @12M for >99.95% patients transplanted with KAS alone was 91.5%. Here, combining KAS+DES may improve outcomes for this high immunologic risk group.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Vo AA, Tang J, Williamson S, Meyers C, Huang E, Zhang X, Haas M, Peng A, Najjar R, Supreet S, Ammerman N, Lim K, Gillespie M, Badash N, Jordan S. Outcomes of Hlai Kidney Transplants in Patients with Cpra 100% After Desensitization [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-hlai-kidney-transplants-in-patients-with-cpra-100-after-desensitization/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences